Disclosed is the use of (a) an anti-connexin 43 agent and (b) a protein or peptide in the preparation of a medicament for treating a delayed or difficult to heal wound, a chronic wound or an ulcer in or on the skin of a subject, wherein the anti-connexin 43 agent comprises an anti-connexin 43 antisense polynucleotide or anti-connexin 43 peptide or peptidomimetic wherein the protein or peptide effective is selected from epidermal growth factor, fibroblast growth factor, connective tissue growth factor, IL-7, secretory leukocyte protease inhibitor, insulin-like growth factor, and insulin-like growth factor binding protein, platelet derived growth factor, an agonist or antagonist of vascular endothelial growth factor, transforming growth factor &bgr3, IL-10, and thymosin 34 wherein the medicament is formulated for separate, sequential or simultaneous administration of (a) and (b).
